Petros Pharmaceuticals Inc (PTPI)
0.6354
+0.05
(+8.54%)
USD |
NASDAQ |
May 31, 16:00
0.6643
+0.03
(+4.55%)
After-Hours: 20:00
Petros Pharmaceuticals Research and Development Expense (Annual): 2.409M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.409M |
| December 31, 2022 | 1.740M |
| December 31, 2021 | 1.788M |
| Date | Value |
|---|---|
| December 31, 2020 | 0.4596M |
| December 31, 2019 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
2019
2.409M
Maximum
2023
1.280M
Average
1.740M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Avalo Therapeutics Inc | 13.78M |
| Imunon Inc | 11.29M |
| iBio Inc | 10.33M |
| Ocugen Inc | 39.57M |
| Gritstone Bio Inc | 127.18M |